Sun Set To Get Taro Deal Over The Line, 17 Years After First Trying

Indian Firm Owns 78.5% Of Taro; Paying $43 Per Share For Remainder

18 Jan 2024

More than a decade after a renewed bid to take control of Taro failed, Sun Pharma is set to take full control of the Israeli-based derma specialist, which has seen material growth and much controversy in the US under Sun’s ownership.

Sun Pharma praised its Israel-based Taro Pharmaceutical subsidiary for “remaining a key player in the generic dermatology market in a challenging environment” as the Indian firm announced that it was paying $43 per share to acquire Taro’s remaining shares, in a bid to shore up the company and ensure it can continue to run profitably.

The Indian firm has held a controlling stake in Taro since 2010, when it exercised an option from its original...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Regulatory Recap: EU Pharma Package Progresses Forward With Extended Data Protection

12 Jun 2025

• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.

Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks

12 Jun 2025

• By Dean Rudge

Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.

Generic Drug Office’s Policy Staff Returning To US FDA

11 Jun 2025

• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.